Cipla will commercially launch Ciplenza in the first week of August, priced at Rs 68 per tablet
Guwahati: Indian pharmaceutical company Cipla announced receiving regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in the country, to be sold under the brand name Ciplenza for restricted treatment of COVID-19 patients.
Cipla will commercially launch Ciplenza in the first week of August, priced at are 68 per tablet.
To ensure fair and equitable distribution of the drug, supplies will be undertaken predominantly through hospital channels and via open channels, prioritised for regions with a high burden of COVID-19 cases.
A statement read, "The drug has been jointly developed by Cipla and CSIR-Indian Institute of Chemical Technology (IICT). As part of this partnership, CSIR-IICT has successfully developed a convenient and cost-effective synthetic process for Favipiravir. The entire process and Active Pharmaceutical Ingredient (API) of the drug has been transferred to Cipla to manufacture and market the drug at scale."
It added that Favipiravir, an oral anti-viral drug has shown to hasten clinical recovery in COVID -19 patients with mild to moderate symptoms.